Serum cotinine cut-points for secondhand smoke exposure assessment in children under 5 years: A systemic review

Nerea Mourino, Alberto Ruano-Raviña, Leonor Varela Lema, Esteve Fernández, María José López, María Isolina Santiago-Pérez, Julia Rey-Brandariz, Alexandra Giraldo-Osorio, Mónica Pérez-Ríos

1 Department of Preventive Medicine and Public Health, University of Santiago de Compostela, Santiago de Compostela, Spain, 2 CIBER Epidemiology and Public Health, CIBERESP, Madrid, Spain, 3 Tobacco Control Unit, WHO Collaborating Center for Tobacco Control, Institut Català d’Oncologia (ICO), Badalona, Spain, 4 Tobacco Control Research Group, Institut d’Investigació Biomèdica de Bellvitge (IDIBELL), Barcelona, Spain, 5 School of Medicine and Health Sciences, Universitat de Barcelona, Barcelona, Spain, 6 CIBER of Respiratory Diseases (CIBERES), Madrid, Spain, 7 Servicio de Evaluación y Métodos de Intervención, Agència de Salut Pública de Barcelona, Barcelona, Spain, 8 Institut d’Investigació Biomèdica de Sant Pau (IIB Sant Pau), Barcelona, Spain, 9 Epidemiology Unit, Galician Directorate for Public Health, Santiago de Compostela, Spain, 10 Departamento de Salud Pública, Grupo de investigación Promoción de la Salud y Prevención de la Enfermedad (GIPSP), Universidad de Caldas, Manizales, Colombia, 11 Fundación Carolina, Madrid, Spain

* leonor.varela@usc.es

Abstract

Background

Serum cotinine has become the most widely used biomarker of secondhand smoke exposure (SHS) over time in all ages. The aim of this study was to review the serum cotinine cut-points used to classify children under 5 years as exposed to SHS.

Methods

A systematic review performed in the Pubmed (MEDLINE) and EMBASE databases up to April 2021 was conducted using as key words “serum cotinine”, “tobacco smoke pollution” (MeSH), “secondhand smoke”, "environmental tobacco smoke" and “tobacco smoke exposure”. Papers which assessed SHS exposure among children younger than 5 years old were included. The PRISMA 2020 guidelines were followed. Analysis was pre-registered in PROSPERO (registration number: CRD42021251263).

Results

247 articles were identified and 51 fulfilled inclusion criteria. The selected studies were published between 1985–2020. Most of them included adolescents and adults. Only three assessed postnatal exposure exclusively among children under 5 years. None of the selected studies proposed age-specific cut-points for children < 5 years old. Cut-point values to assess SHS exposure ranged from 0.015 to 100 ng/ml. The most commonly used
cut-point was 0.05 ng/ml, derived from the assay limit of detection used by the National Health and Nutrition Examination Survey (NHANES).

Conclusions
No studies have calculated serum cotinine age-specific cut-points to ascertain SHS exposure among children under 5 years old. Children’s age-specific cut-points are warranted for health research and public health purposes aimed at accurately estimating the prevalence of SHS exposure and attributable burden of disease to such exposure, and at reinforcing 100% smoke-free policies worldwide, both in homes, private vehicles and public places.

Introduction
The assessment of the involuntary smoking or exposure to secondhand smoke (SHS) in children during pregnancy and early childhood is essential for public health and research purposes. Estimating the children at-risk from environmental tobacco can have important public health implications in terms of determining the population attributable burden of disease and evaluating the impact of the information, cessation interventions and prohibition laws on this target group. SHS is defined as tobacco smoke produced by an active smoker from exhaled mainstream smoke together with sidestream smoke. Sidestream smoke is a combination of smoke from the smoldering tobacco product between and during puffs and smoke components which diffuse through cigarette paper [1,2].

Pediatric population is especially vulnerable to the effects of SHS due to their narrower bronchi, faster respiratory rate and immature immune system [3]. Prejudicial effects derived from SHS exposure on children’s health have been documented since the 1970s, including but not limited to the following: increased risk of sudden infant death syndrome, acute respiratory symptoms (cough, phlegm, wheeze and breathlessness) and ear infections [1]. In 2004, 165,071 deaths among children younger than 5 years were attributed worldwide to SHS exposed [4]. However, these estimations were considered to be prone to bias because exposure data was mainly derived from surveys. Parental self-report questionnaires have been widely used to assess both prenatal and postnatal SHS exposure [5,6] but frequently provide underestimations due to parents’ reluctance to disclose their smoking status and underreporting of children’s SHS exposure, as well as the recall bias or lack of knowledge of exposure [6,7]. This highlights the need for objective methods based on the determination of biomarkers to provide reliable assessment of SHS exposure [5].

Cotinine, the major metabolite of nicotine, is considered the best biomarker for assessing recent SHS exposure due to its high specificity and sensitivity, as well as its relatively prolonged half-life which ranges from 16 to 20 hours in children [6,8]. Cotinine can be collected from various biological samples such as blood (serum/plasma), urine, saliva, hair, meconium and maternal milk, and quantified through several analytical techniques [6,8–10]. Although the collection of serum or plasma cotinine is more invasive than that from other samples, it is not influenced by renal function, flow rate, and urinary pH and it does not require urine dilution adjustments; over time, serum cotinine has become the most widely used biomarker of SHS exposure among children [1,6].

Serum cotinine allows for differentiating active smokers from passive and non-smokers. Nonetheless, the determination of SHS exposure is rather challenging as currently there is no standardized consensus regarding the optimal cut-point to be used to classify SHS exposure
among young children. Some prior studies, based on NHANES data for older children and adolescents, proposed the serum cotinine cut-point of 0.05 ng/ml which derives from the assay limit of detection (LOD) [8,11]. This cut-point maximizes sensitivity to avoid missing positive cases, but it should be acknowledged that a trade-off always exists between sensitivity and specificity, and cotinine metabolism and clearance can vary by sex, race and age [1,5]. Considering that children’s physiology is quite different within the 0–5 years old age range, age-specific cut-points might be useful for different studies to accurately classify nonsmoking children as exposed or unexposed to tobacco smoke in a standardized manner [5]. As far as we are aware of, there are no reviews focused on the serum cotinine cut-points used to classify SHS exposure in the pediatric population.

The aim of this study is to review serum cotinine cut-points used so far to assess SHS exposure in children under 5 years and assess the changes on the cut-point values over time and across different countries.

**Material and methods**

**Literature search**

We performed a systematic review in PubMed (MEDLINE) and EMBASE databases following the PRISMA 2020 guidelines [12]. Search included papers published until April 2021 and “serum cotinine”, “Tobacco smoke pollution” (MeSH), “secondhand smoke” and “environmental tobacco smoke” were used as key words. Search strategy underwent peer review by three knowledgeable reviewers. Age filters were set (newborns-infant-preschool child). No reports, communications to congresses or simulation essays were included. The bibliographic search was limited to English, Spanish, French and German. Analysis was pre-registered in PROSPERO (registration number: CRD42021251263).

**Inclusion/Exclusion criteria**

To be selected for this review, articles had to assess pre-natal SHS exposure in newborns and/or post-natal SHS exposure in children younger than 5 years by using serum cotinine assays in addition to or in lieu of parental self-report. We included investigations with mother-child-pairs and those grouping children under 5 with older ones, adolescents and adults. Among the latter, when data was stratified by age groups, we selected that including children younger than 5 years. On the other hand, we excluded studies with serum cotinine obtained just from mothers; without cut-point values to distinguish between exposed and unexposed children, and those measuring cotinine from other biological fluids as urine, saliva, hair, meconium or maternal milk. In the case of longitudinal studies, we only considered the information corresponding to the period of time in which SHS exposure was ascertained accompanied with serum cotinine in a sample including children under 5 years.

**Selection of articles and evidence synthesis**

After excluding duplicate articles from the search, the title and abstract of the records were screened individually by two independent reviewers to ascertain that they met eligibility criteria. Full text of the eligible papers was obtained for potentially relevant articles. Bibliography from the selected papers was revised to manually complete the initial search. Thereafter, data from those meeting eligibility criteria were extracted and discrepancies in its interpretation were solved by consensus. A modified Newcastle-Ottawa scale was used to assess appropriateness of the representativeness of the sample, participation rate, ascertainment of the exposure, and the adequacy of the method used for the selection of the cut-points. Score
disagreements were resolved by consensus and a final agreed-upon rating was assigned to each study.

The data extracted for analysis were: study characteristics (author, publication year, design, period of the study, use of questionnaire in conjunction with cotinine (yes/no) and country); population characteristics (sample size, age and race); information regarding the analytical technique used to quantify serum cotinine (radioimmunoassay (RIA), enzyme-linked immunosorbent essay (ELISA), gas chromatography (GC), gas-chromatography mass spectrometry (GC/MS), gas-liquid chromatographic procedure with nitrogen-phosphorus-specific detector (GLC/NPD) and isotope dilution liquid chromatography tandem mass spectrometry (LC-MS)); serum cotinine cut-point values to classify SHS exposure in children and method for the selection of the cut-points.

Results

A total of 247 articles were obtained and 51 of them fulfilled the inclusion criteria. The PRISMA flow diagram of the included studies is displayed in Fig 1.

![PRISMA flow diagram](https://doi.org/10.1371/journal.pone.0267319.g001)
Study and population characteristics

The 51 papers included were published between 1985 and 2020. They included one case-control study [13], 13 cohort studies [14–26] and 37 [27–63] cross-sectional studies from which, one included a matched case-control substudy [53]; 26 studies obtained data from different cycles of the National Health and Nutrition Examination Survey (NHANES). When applying the modified Newcastle-Ottawa scale, two cohort studies [17,19] and one cross-sectional study [36], which used data from the NHANES, were judged to be of high quality, and thirty six studies were judged to be of low quality.

Studies were mainly conducted in the USA (34 papers) and Europe (15 studies) (Fig 2).

Thirty-three out of 51 papers measured postnatal exposure to SHS with serum cotinine; 17 prenatal exposure with newborns’cord serum cotinine and one both pre- and post-natal exposure [19]. 38 studies ascertained exposure by using both serum cotinine and questionnaires (Table 1).

Considering those studies assessing prenatal exposure, sample sizes ranged from 8 to 1,323 newborns. Among the 33 studies assessing postnatal exposure, 27 papers grouped children under 5 years with older/adolescents (aged 12–19) and 3 papers, also with adults (aged ≥ 20). The remaining 3, measured postnatal SHS exposure exclusively in children under 5 years with sample sizes ranging from 132 to 504 children [14,56,59] (Table 1 and Fig 2).

Analytical technique, cut-point value/s, and method for cut-point identification

Isotope dilution liquid chromatography tandem mass spectrometry (LC-MS) was used in 35 of the selected papers followed by RIA in 7, GC/GC-MS/ GLC/NPD in 7 and ELISA in 2 (Fig 2).
Table 1. Study and population characteristics; analytical technique for serum cotinine quantification; cotinine cut-points (CP) and method for their selection.

| Author, yr | Design and period | Questionnaire (yes/no) | Country | Sample size | Age | Race | Analytic technique | CP (ng/ml) | Method Reference |
|------------|-------------------|------------------------|---------|-------------|-----|------|-------------------|------------|------------------|
| Luck et al, 1985 [27] | Cross-sectional, N/A | Yes | Germany | 8 | Newborns | N/A | GLC/NPD | 5 | Assay LOD | 27 |
| Ahlsten et al, 1989 [28] | Cross-sectional, N/A | Yes | Sweden | 39 | Newborns | N/A | GC | 1 | Assay LOD | 28 |
| Etzel et al, 1992 [14] | Cohort study, 1964–1983 | No | USA | 132 | 4 months-3 yr | White, black or mixed race | RIA | 2.5 | ROC curves | 14 |
| Bardy et al, 1993 [31] | Cross-sectional, 1991 | Yes | Finland | 1,237 | Newborns | N/A | GC/MS | 6 | Assay LOD | 31 |
| CDC, 1993 [29] | Cross-sectional (NHANES, 1988–1991) | Yes | USA | 800† | 4–91 yr | N/A | LC/MS | 10/15 | Authors selected the CP value from a separation point in the bimodal distribution of SC in smokers and nonsmokers | 29 |
| Bardy et al, 1994 [30] | Cross-sectional, 1991 | Yes | Finland | 1,323 | Newborns | N/A | GC/MS | 35 | Assay LOD | 30 |
| Martinez et al, 1994 [15] | Cohort Study, 1980–1984 | Yes | USA | 175 | Newborns | Hispanic or other non-Anglo | RIA | 1 | Assay LOD | 15 |
| Ruhle et al, 1995 [32] | Cross-sectional, N/A | Yes | Germany | 75 | Newborns | N/A | RIA | 15 | Authors selected the CP value based on data from a previous study | 32 |
| Pirkle et al, 1996 [17] | Cross-sectional (NHANES, 1988–1991) | Yes | USA | 1,793‡ | 4–11 yr | Non-Hispanic white, non-Hispanic black, Mexican American or other | LC/MS | 10/15 | Authors selected the CP value from a separation point in the bimodal distribution of SC in smokers and nonsmokers | 33 |
| Nafstad et al, 1996 [16] | Cohort study, 1992–1993 | Yes | Norway | 202 | Newborns | N/A | RIA | 14 | Authors selected the CP value based on data from a previous study | 16 |
| Bearer et al, 1997 [13] | Case-control, 1991–1992 | Yes | USA | 70 | Newborns | Non-Hispanic white, non-Hispanic black or other (Hispanic and Asian) | GC/MS | 1 | Assay LOD | 13 |
| Pichini et al, 2000 [17] | Cohort Study, 1997–1998 | Yes | Spain | 429 | Newborns | N/A | RIA | 1.78 | ROC curves | 17 |
| Mannino et al, 2001 [34] | Cross-sectional (NHANES, 1988–1994) | Yes | USA | 1,533 | 4–6 yr | Non-Hispanic white, non-Hispanic black or Mexican American | LC/MS | 0.05 | Assay LOD | 34 |
| Strauss, 2001 [35] | Cross-sectional (NHANES, 1988–1991) | Yes | USA | 2,968‡ | 4–18 yr | N/A | LC/MS | 2 | Author selected the CP value based on data from a previous study | 35 |
| Mannino et al, 2001 [36] | Cross-sectional (NHANES, 1989–1994) | Yes | USA | 5,653‡ | 4–16 yr | Non-Hispanic white, non-Hispanic black or Mexican American | LC/MS | 0.05 | Assay LOD | 36 |
| Lieu et al, 2002 [37] | Cross-sectional (NHANES, 1989–1994) | Yes | USA | 1,825‡ | 4–12 yr | Non-Hispanic white, non-Hispanic black or Mexican American | LC/MS | 10/20 | Authors selected the CP value based on data from a previous study | 37 |

(Continued)
| Author, yr | Design and period | Questionnaire (yes/no) | Country | Sample size | Age | Race | Analytical technique | CP (ng/ml) | Method Reference |
|------------|--------------------|------------------------|---------|-------------|-----|------|----------------------|------------|------------------|
| Mannino et al, 2002 [38] | Cross-sectional (NHANES, 1989–1994) | No | USA | 523‡ | 4–16 yr | Non-Hispanic white, non-Hispanic black or Mexican American | LC/MS | 0.05 | Assay LOD 38 |
| Rubin et al, 2004 [39] | Cross-sectional (NHANES, 1989–1994) | Yes | USA | 6,153‡ | 4–16 yr | N/A | LC/MS | 2.9 | Authors selected both CP values based on data from a previous study 39 |
| Aligne et al, 2003 [40] | Cross-sectional (NHANES, 1989–1994) | No | USA | 3,531‡ | 4–11 yr | Non-Hispanic white, non-Hispanic black, Mexican American or other | LC/MS | 0.05 | Assay LOD 40 |
| Wilkinson et al, 2006 [41] | Cross-sectional (NHANES, 1989–1991) | Yes | USA | 2,516‡ | 4–16 yr | Non-Hispanic white, non-Hispanic black, Mexican American or other | LC/MS | 0.05 | Assay LOD 41 |
| Pirkle et al, 2006 [42] | Cross-sectional (NHANES, 1989–2002) | Yes | USA | 1988–91: 1,839‡ | 1991–94: 2,090‡ | 1999–2000: 1,065‡ | 2001–2002: 1,278‡ | 4–11 yr | Non-Hispanic white, non-Hispanic black, Mexican American or other | LC/MS | 0.05 | Assay LOD 42 |
| Franchini et al, 2008 [43] | Cross-sectional, 2004–2005 | Yes | Italy | 979 | Newborns | Italian or foreign | GC/MS | 1 | Authors selected the CP value based on data from previous studies 43 |
| Puig et al, 2008 [18] | Cohort Study, 1996–1998. | Yes | Spain | 487 | Newborns | Spanish or non-Spanish | RIA | 1 | Authors selected the CP value based on data from a previous study 18 |
| Max et al, 2009 [44] | Cross-sectional (NHANES, 1999–2006) | Yes | USA | 1999–2000: 1,179‡ | 2001–2002: 1,423‡ | 2003–2004: 1,265‡ | 2005–2006: 1,306‡ | 3–11 yr | Non-Hispanic white, non-Hispanic black, Mexican American, other Hispanic or other race/ethnicity | LC/MS | 0.05 | Assay LOD 44 |
| Dixon et al, 2009 [29] | Cross-sectional (NHANES, 1999–2004) | Yes | USA | 829‡ | 1–5 yr | Non-Hispanic white, non-Hispanic black, Hispanic or other | LC/MS | 0.05 | Assay LOD 45 |
| CDC (Vital signs), 2010 [46] | Cross-sectional (NHANES, 1999–2008) | Yes | USA | N/A | 3–11 yr | Non-Hispanic white, non-Hispanic black, Mexican American or other | LC/MS | 0.05 | Assay LOD 46 |
| Dove et al, 2010 [47] | Cross-sectional (NHANES, 1999–2006) | Yes | USA | 1,582‡ | 3–5 yr | Non-Hispanic white, non-Hispanic black, Mexican American or other | LC/MS | 0.05 | Assay LOD 47 |
### Table 1. (Continued)

| Author, yr | Design and period | Questionnaire (yes/no) | Country | Sample size | Age | Race | Analytical technique | CP (ng/ml) | Method Reference |
|------------|-------------------|------------------------|---------|-------------|-----|------|----------------------|------------|------------------|
| Vesper et al, 2010 [48] | Cross-sectional (NHANES, 2003–2004) | No | USA | N/A | 3–11 yr | Non-Hispanic white, non-Hispanic black or Mexican American | LC/MS | 10 | Authors selected the CP value based on data from a previous study |
| Xu et al, 2010 [49] | Cross-sectional (NHANES, 2001–2002) | No | USA | 4,508‡ | 4–15 yr | Non-Hispanic white, non-Hispanic black, Mexican American or other | LC/MS | 0.035 | Authors selected CP values based on the 33rd and 67th percentiles of the SC concentrations |
| Preston et al, 2010 [50] | Cross-sectional, 2004–2005 | Yes | USA | 30 Newborns | Asian, Caucasian or African American | LC/MS | 1 | Authors selected the CP value based on data from a previous study |
| Sharief et al, 2011 [51] | Cross-sectional (NHANES, 2005–2006) | No | USA | 3,136† | 1–21 yr | Non-Hispanic white, non-Hispanic black, Mexican American or other | LC/MS | 2.9 | Authors selected the CP value based on data from a previous study |
| Spanier et al, 2011 [19] | Cross-sectional, 2004–2005 | Yes | USA | Newborns: 273 1 yr: 275 2 yr: 206 Newborns-2 yr | Non-Hispanic White, non-Hispanic Black or other | LC/MS | 0.015 | ROC curves; 0.9 ng/ml for children aged < 12 yr; 0.6 ng/ml for those aged ≥12 yr. |
| Cardwell et al, 2012 [52] | Cross-sectional, N/A | No | USA | 220‡ | 1–16 yr | N/A | LC/MS | 0.9 | ROC curves; 0.9 ng/ml for children aged < 12 yr; 0.6 ng/ml for those aged ≥12 yr. |
| Dempsey et al, 2012 [53] | Cross-sectional with a matched case control substudy, 2009–2010 | Yes | USA | 274‡ | 8 months-17 yr (70% were < 3 yr) | Latino, African American, Asian, White non-Hispanic or other | LC/MS | 0.05 | Assay LOD |
| Florath et al, 2014 [20] | Cohort Study, 2000–2001 | Yes | Germany | 972 Newborns | German or non-German | LC/MS | 14 | Assay LOD |
| Wang et al, 2013 [21] | Cohort study | Yes | China | 14 Newborns | N/A | LC/MS | 0.12 | Authors selected the CP value based on the median cotinine levels of the entire cohort |
| Andersen et al, 2013 [54] | Cross-sectional, 1988–1990 | No | Denmark | 133 Newborns | N/A | Immulite 2000 | 5 | Authors selected the CP values based on data from a previous study |
| Kit et al, 2013 [55] | Cross-sectional (NHANES, 1988–2010) | Yes | USA | 1988–1994: 248‡ 1999–2004: 336‡ 2005–2010: 392‡ | 4–11 yr | Non-Hispanic White, non-Hispanic Black, Mexican American or other | LC/MS | 0.05 | Assay LOD |
| Howrylak et al, 2014 [22] | Cohort Study, 2010–2011 | Yes | USA | 619 | 1–16 yr | White, African American, Multiracial or other | LC/MS | 0.1 | Assay LOD |
| Pino et al, 2004 [56] | Cross-sectional, 1995–1997 | No | Chile | 504 | 1 yr | N/A | RIA | 100 | Assay LOD (from a study conducted in 1987) |

(Continued)
| Author, yr          | Design and period         | Questionnaire (yes/no) | Country | Sample size | Age   | Race                              | Analytical technique | CP (ng/ml) | Method Reference |
|---------------------|---------------------------|------------------------|---------|-------------|-------|-----------------------------------|----------------------|------------|------------------|
| Mason et al, 2015 [57] | Cross-sectional (NHANES, 2007–2010) | No                     | USA     | N/A†        | ≥ 3 yr | N/A                               | LC/MS                | 0.05       | Assay LOD 57     |
| West et al, 2015 [23] | Cohort Study, 1980–2014    | Yes                    | Finland | 1,578‡      | 3–18 yr | N/A                               | GC                   | 3          | Authors selected CP based on data from a previous study 23 |
| Merianos et al, 2017 [58] | Cross-sectional (NHANES, 2009–2012) | No                     | USA     | 2,707‡      | 3–11 yr | Non Hispanic White, non Hispanic-Black, Hispanic, other races/multiracial | LC/MS                | 0.05       | Assay LOD 58     |
| Yilmaz et al, 2018 [59] | Cross-sectional, 2012–2013 | No                     | Turkey  | 150         | 1–3 yr  | N/A                               | ELISA                | 3          | Authors selected CP based on data from a previous study 59 |
| Shenassa et al, 2017 [60] | Cross-sectional (NHANES, 1999–2012) | Yes                    | USA     | 2,679‡      | 3–5 yr  | Non-Hispanic White, non-Hispanic Black, Mexican American or other | LC/MS                | 10         | Authors used CP value based on data from a previous study 60 |
| Hedengran et al, 2018 [24] | Cohort study, 2003–2004     | Yes                    | Denmark | 263         | Newborns | N/A                               | LC/MS                | 0.2        | Authors selected CP based on data from a previous study 24 |
| Nwosu et al, 2018 [61] | Cross-sectional (NHANES, 2009–2010) | No                     | USA     | 1,013≤      | 3–9 yr  | Non-Hispanic White, Mexican American, Other Hispanics, African American or other | LC/MS                | 0.05       | Assay LOD 61     |
| Chelchowska et al, 2019 [25] | Cohort study, 2013–2015    | Yes                    | Poland  | 80          | Newborns | Caucasian                         | ELISA                | 13.7       | Authors selected CP based on data from a previous study 25 |
| Brody et al, 2019 [62] | Cross-sectional (NHANES, 2013–2016) | Yes                    | USA     | 2,833‡      | 3–11 yr | Non-Hispanic White, non-Hispanic Black, non-Hispanic Asian or Hispanic | LC/MS                | 0.05       | Assay LOD 62     |
| Biren et al, 2020 [63] | Cross-sectional (NHANES, 2015–2016) | Yes                    | USA     | 257         | 3–5 yr  | Non-Hispanic white, non Hispanic-black, Mexican-American, other Hispanic or other/multiracial | LC/MS                | 0.05       | Assay LOD 63     |
| Rovio et al, 2020 [26] | Cohort study, 1980–2011     | Yes                    | Finland | 1,504‡      | 3–18 yr | N/A                               | LC/MS                | 3          | Authors used CP value based on data from a previous study 26 |

Abbreviations: N/A, not available; GLC/NPD, gas-liquid chromatographic procedure with nitrogen-phosphorus-specific detector; LOD, limit of detection; GC, gas chromatography; USA, United States of America; yr, year; RIA, radioimmunoassay; ROC, receiver operating characteristic; GC/MS, Gas- chromatography mass spectrometry; NHANES, National Health and Nutrition Examination Survey; LC/MS, isotope dilution-liquid chromatography-tandem mass spectrometry; CP, cut-point; SC, serum cotinine; SHS, secondhand smoke; ELISA, Enzyme-linked immunosorbent essay.

†Sample sizes include children (3–11 yr), adolescents (12–19 yr) and adults (> 19 yr).
‡Sample size includes children aged 5 years and older.

https://doi.org/10.1371/journal.pone.0267319.t001
A total of 26 studies mentioned the assay LOD threshold as cut-point (Fig 2). In order to ascertain SHS exposure among children, cut-point values ranged between 0.015–35 ng/ml, excepting in one study that used 100 ng/ml; the most commonly used threshold was 0.05 ng/ml (17 out of 51) (Table 1). Eighteen articles selected the serum cotinine cut-point value/s based on previous studies (Fig 2). The lowest value was mentioned in North American studies and the highest, in a Chilean study [56].

One study calculated age-specific cut-point with receiver operating characteristic (ROC) curves [52]: 0.9 ng/ml (<12 years) vs. 0.6 ng/ml (≥/12 years). However, none of the selected articles proposed sex, race or age-specific serum cotinine cut-points in children under 5 years.

**Discussion**

As summarized in Table 1, the cut-points to classify SHS exposure varied widely between studies. None of these studies have proposed age-specific cut-points to classify SHS exposure in children under 5 years. Only one study calculated two age-specific cut-points setting the reference age at 12. Commonly, SHS exposure thresholds were established attending to the assay LOD or based on previously defined adolescent and adult cut-points without accounting for population characteristics, analytical technique or prevalence of SHS exposure in the country of the study.

Several studies have concluded that cotinine metabolism is influenced by sex, race and age after having observed higher cotinine concentrations among children, females and non-Hispanic Blacks [42,44,64]. With respect to age, young children seem to have higher serum cotinine concentrations than older/adolescents and nonsmokers adults at similar exposures to SHS and this could be due to differences in cotinine metabolism and clearance. However, young children could also be more exposed to SHS due to faster respiratory rate, inability to distract themselves or breastfeeding by smoking mothers [42,64–66]. The NHANES, which has measured SHS exposure since 1988 by using questionnaires and serum cotinine, found higher cotinine concentrations among children aged 3–11 years compared to adolescents aged 12–19 years and adults [42,67].

In our systematic review, we have observed that serum cotinine cut-point values to characterize children’s exposure to SHS have varied remarkably since 1985 and across the countries, being the highest value mentioned in a Chilean study conducted in 1990s, more than 6,600 times that of the lowest used in US studies, 100 versus 0.015 ng/ml. European studies used values between 0.2–35 ng/ml. We only found three studies assessing postnatal exposure exclusively among children under 5 years, between 1–3 years, with disparate cut-points ranging from 2.5 ng/ml to 100 ng/ml.

We have observed that some of the studies that classified pre- or postnatal SHS exposure selected the threshold used to distinguish between smoker and non smoker (ranging from 3 to 20 ng/ml) and thus, being liable to have underestimate exposure on this target group. The only paper included in our review, which measured both pre- and postnatal exposure to SHS with serum cotinine, used the same cut-point for newborns and children aged 1 and 2 years [19].

The most widely used cut-point for the classification of prenatal SHS exposure, via newborns’ cord serum cotinine, was 1 ng/ml; One study obtained a cut-point of 1.78 ng/ml from the ROC curves to discriminate newborns from nonexposed and exposed nonsmokers with a sensitivity and specificity of 60% [17]; this value exceeds some of those used to classify exposure among young children. However, taking into consideration the transfer of serum cotinine to fetus across the placenta and the higher metabolism and faster clearance of cotinine in pregnant women, it can not be disregarded that newborns may have lower cotinine concentrations than young children for the same exposure levels. Nonetheless, it should be acknowledged that
the characterization of SHS prenatal exposure from cord serum cotinine samples from the newborn could be imprecise; taking into account that newborn refers to the moment of delivery and that the measured cotinine concentrations might cover the period of time in which women may be hospitalised [24,43].

In general terms, a decrease in the serum cotinine cut-point values has been observed over time and this could be partly explained by the better LOD threshold of the analytical techniques. Beginning in 2001–2002, the LC/MS assay LOD used to determine serum cotinine concentrations in the samples collected in NHANES was lowered in some studies from 0.05 to 0.015 ng/ml as a result of the introduction of a more sensitive mass spectrometer [42]. These two have been the LOD derived cut-points most widely used over time to classify exposure to SHS in the USA. Of note, it should be acknowledged that serum cotinine, like other biomarkers, has an important limitation, being that it does not provide information on the route and source of exposure. Although the main health risks associated with SHS are related to inhalation of fine particulate and gases from sidestream smoke [2,68], values around 0.015 ng/ml could reflect not only transient and accidental SHS exposure (sometimes unnoticed by children’s caregivers), but also third-hand smoke exposure (THS) or residual tobacco smoke (such as involuntary inhalation, ingestion or cutaneous absorption of nicotine particles from SHS deposited on surfaces, clothing or furniture which remain there long after smoke is gone) or exposure from other sources such as food. Thus, a child ingesting nicotine laden dust through crawling or hand-to-mouth activity (THS exposure) may have high serum cotinine from ingesting that dust, but could have experienced very little exposure to SHS. Previous studies reported that certain foodstuffs such as potatoes, tomatoes, eggplant, cauliflower, green peppers and black tea have measurable levels of nicotine [69,70]. Whilst food consumption levels of dietary nicotine are insignificant compared with moderate SHS exposure, the consumption of high quantities might contribute to low-level elevations in serum cotinine (e.g. 80 g of eggplant is equivalent to approximately 0.01 ng/ml of serum cotinine) [8]. Further studies in children could verify this hypothesis using detailed dietary information and sensitive cotinine biomarkers; this information could be useful to propose high level cut-points that could allow for a better characterization of the SHS exposure in children, differentiating significant exposure from minor or incidental exposure.

The lowering of the thresholds also results from the acknowledgement that no safe levels of SHS exposure can be established. Some prior investigators have emphasized that even very low levels of SHS exposure (serum cotinine concentrations < 0.1 ng/mL) can cause adverse effects on cognitive outcomes among children [71] and this could be also attributed to the higher lead concentrations found in children exposed to SHS compared to those unexposed [72]. In the USA, as a result of combined tobacco control policies, prevalence of tobacco consumption and SHS exposure have declined during the last 3 decades. Consequently, serum cotinine cut-points have become lower to be able to avoid misclassifying any SHS even at low level or accidental exposure [73]. Whilst these revised lower cut-points could be recommended from a health perspective, they could lead to an overestimation of the population exposure to SHS because as already mentioned, there is always a trade off between sensitivity and specificity. In this case, this lowering of the cut-point can lead to a higher false positive rate. This could impact on the calculations of SHS exposure in a given population and in term, on the estimated attributable burden of disease. The lack of consensus with respect to the most appropriate cut-point has also important implications with regards to the comparison of data and trend analysis.

This review has some limitations. First, we only used PubMed and EMBASE databases but we do not expect to have missed any relevant papers because we have expanded the search by including articles from the bibliography of those papers selected. Second, when limiting the
search to English, Spanish, French and German, papers published in other languages might have been excluded. To the best of our knowledge, 1 paper published in Polish was excluded. Third, period of study was not specified in 4 cross-sectional studies [27,28,32,52]. Another limitation is the low sample size of some investigations with 3 articles without specification of the participants’ sample size [46,48,57]. Finally, 36 out of 51 studies were judged to be of low quality when applying the modified Newcastle-Ottawa scale, and the majority of the included studies grouped children under 5 years with older and adolescents, being this one the main limitation.

As the main strength, this is the first review on the serum cotinine cut-points used across different countries to assess SHS exposure in children. Prior investigations have identified the cotinine cut-point values used over time to discriminate between smokers and non-smokers. The 2006 Surgeon General’s report mentioned the need to review the cut-points used when assessing tobacco consumption and SHS exposure among pregnant women considering the higher metabolic clearance rates and therefore, the shorter half-life of cotinine during pregnancy [1]. For those studies which found discrepancies between self-report and serum cotinine, most assumed that parents did not accurately report their child’s SHS exposure [15,18,53]. One study considered the possibility of misclassification due to the inadequacy of the cut-point [40]. A recent cohort study assessing SHS exposure among children younger than 5 years, observed that, compared to the assay LOD derived cut-point of 0.015 ng/ml, when using new age-specific cut-points, all of them higher than the mentioned assay threshold, concordance between maternal self-report and serum cotinine improved; actually, the percentage of children reclassified as SHS exposed with cotinine diminished in approximately fifty percentage points when using the age-specific cut-points obtained with ROC curves [74].

It is necessary to raise public awareness of the need to adopt 100% smoke-free policies worldwide aimed at avoiding the long-term adverse effects resulting from early exposures to tobacco smoke. SHS exposure has been associated with cognitive impairment and chronic diseases (such as respiratory and cardiovascular diseases) which begin early in childhood and cause premature disability, death and high healthcare costs. Thus, adequate classification of SHS exposure is warranted to accurately estimate the prevalence of SHS exposure and the attributable burden of disease to such exposure. Biomarker assessment of SHS provides an advantage over questionnaire assessment with respect to their accuracy; however, valid non-biased cotinine cut-points are needed. Considering that young children are especially vulnerable to the health consequences derived from SHS exposure, and the developmental changes in child behaviour, anatomy and physiology during the first years of life, further well-designed studies would be recommended to propose age-specific serum cotinine cut-points or multiple cut-point values which maximises both sensitivity and specificity to minimise misclassification either as exposed or unexposed based on cotinine concentrations.

**Conclusions**

No studies have calculated serum cotinine age-specific cut-points to ascertain SHS exposure among children under 5 years old. The adverse health consequences derived from any level of SHS exposure, especially from the sidestream smoke, and the developmental changes in child behaviour, anatomy and physiology during the first years of life, support the need for age-specific cut-points for health research and public health purposes aimed at accurately estimating SHS exposure and attributable burden of disease to such exposure, and at reinforcing 100% smoke-free policies worldwide, both in homes, private vehicles and public places.
Supporting information
S1 Checklist. PRISMA checklist.

Author Contributions
Conceptualization: Nerea Mourino, Alberto Ruano-Raviña, Leonor Varela Lema, Mónica Pérez-Ríos.
Data curation: Nerea Mourino, Alberto Ruano-Raviña, Leonor Varela Lema, Mónica Pérez-Ríos.
Formal analysis: Alberto Ruano-Raviña, Leonor Varela Lema.
Investigation: Nerea Mourino.
Methodology: Nerea Mourino, Alberto Ruano-Raviña, Leonor Varela Lema, Esteve Fernández, María José López, María Isolina Santiago-Pérez, Mónica Pérez-Ríos.
Supervision: Alberto Ruano-Raviña, Leonor Varela Lema, Esteve Fernández, María José López, María Isolina Santiago-Pérez, Julia Rey-Brandariz, Alexandra Giraldo-Osorio, Mónica Pérez-Ríos.
Visualization: Nerea Mourino, María Isolina Santiago-Pérez.
Writing – original draft: Nerea Mourino, Alberto Ruano-Raviña, Leonor Varela Lema.
Writing – review & editing: Nerea Mourino, Alberto Ruano-Raviña, Leonor Varela Lema, Esteve Fernández, María José López, María Isolina Santiago-Pérez, Julia Rey-Brandariz, Alexandra Giraldo-Osorio, Mónica Pérez-Ríos.

References
1. U.S. Department of Health and Human Services. The Health Consequences of Involuntary Exposure to Tobacco Smoke: A Report of the Surgeon General. Atlanta: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, Coordinating Center for Health Promotion, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health. 2006.
2. Jaakkola MS, Jaakkola JJ. Assessment of exposure to environmental tobacco smoke. Eur Respir J. 1997; 10(10):2384–97. https://doi.org/10.1183/09031936.97.10102384 PMID: 9387970
3. Hang B, Wang P, Zhao Y, Sarker A, Chenna A, Xia Y, et al. Adverse Health Effects of Thirdhand Smoke: From Cell to Animal Models. Int J Mol Sci. 2017; 18(5): 932. https://doi.org/10.3390/ijms18050932 PMID: 28452951
4. Öberg M, Jaakkola MS, Woodward A, Peruga A, Prüss-Ustün A. Worldwide burden of disease from exposure to second-hand smoke: a retrospective analysis of data from 192 countries. The Lancet. 2011; 377(9760):139–46. https://doi.org/10.1016/S0140-6736(10)61388-8 PMID: 21112982
5. Kim S. Overview of Cotinine Cutoff Values for Smoking Status Classification. Int J Environ Res Public Health. 2016; 13(12). https://doi.org/10.3390/ijerph13121236 PMID: 27983665
6. Florescu A, Ferrence R, Einarson T, Selby P, Soldin O, Koren G. Methods for quantification of exposure to cigarette smoking and environmental tobacco smoke: focus on developmental toxicity. Ther Drug Monit. 2009; 31(1):14–30. https://doi.org/10.1097/FTD.0b013e3181957a3b PMID: 19125149
7. Aurrekoetxea JJ, Murcia M, Rebagliato M, Guexens M, Fernández-Somoano A, López MJ, et al. Second-hand smoke exposure in 4-year-old children in Spain: Sources, associated factors and urinary cotinine. Environ Res. 2016; 145:116–25. https://doi.org/10.1016/j.envres.2015.11.028 PMID: 28656512
8. Benowitz NL. Cotinine as a biomarker of environmental tobacco smoke exposure. Epidemiol Rev. 1996; 18(2):188–204. https://doi.org/10.1093/oxfordjournals.epirev.a017925 PMID: 9021312
9. Braun JM, Kalloo G, Chen A, Dietrich KN, Liddy-Hicks S, Morgan S, et al. Cohort Profile: The Health Outcomes and Measures of the Environment (HOME) study. Int J Epidemiol. 2017; 46(1):24. https://doi.org/10.1093/ije/dyw006 PMID: 27006352

10. Luck W, Nau H. Exposure of the fetus, neonate, and nursed infant to nicotine and cotinine from maternal smoking. N Engl J Med. 1984; 311(10):672. https://doi.org/10.1056/NEJM19840906311014 PMID: 6472348

11. Levy RV, Brathwaite KE, Sarathy H, Reidy K, Kassel FH, Melamed ML. Analysis of Active and Passive Tobacco Exposures and Blood Pressure in US Children and Adolescents. JAMA Netw. Open. 2021; 4(2). https://doi.org/10.1001/jamanetworkopen.2020.37936 PMID: 3360445

12. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Syst Rev. 2021; 10(1):89. https://doi.org/10.1186/s13643-021-01626-4 PMID: 33781348

13. Bearer C, Emerson RK, O'Riordan MA, Roitman E, Shackleton C. Maternal tobacco smoke exposure and persistent pulmonary hypertension of the newborn. Environ Health Perspect. 1997; 105(2):202–6. https://doi.org/10.1289/ehp.9710520 PMID: 9105795

14. Etzel RA, Pattishall EN, Haley NJ, Fletcher RH, Henderson FW. Passive smoking and middle ear effusion among children in day care. Pediatrics. 1992; 90(2 Pt 1):228–32. PMID: 1641287

15. Martinez FD, Wright AL, Taussig LM. The effect of paternal smoking on the birthweight of newborns. Pediatrics. 1984; 73(5):734–6. https://doi.org/10.1542/peds.73.5.734 PMID: 6780782

16. West HW, Juonala M, Gall SL, Kahonen M, Laitinen T, Taittonen L, et al. Exposure to parental smoking in childhood is associated with increased risk of carotid atherosclerotic plaque in adulthood: the Cardiovascular Risk in Young Finns Study. Circulation. 2015; 131(14):1239–46. https://doi.org/10.1161/CIRCULATIONAHA.114.013485 PMID: 25802269

17. Chininis S, Basagaña X, Pacifi ci R, Garcia O, Puig C, Vall O, et al. Cord serum cotinine as a biomarker of fetal exposure to cigarette smoke at the end of pregnancy. Environ Health Perspect. 2000; 108(11):1079–83. https://doi.org/10.1289/ehp.001081079 PMID: 11102300

18. Puig C, Garcia-Algar O, Monleon T, Pacifi ci R, Zuccaro P, Sunyer J, et al. A longitudinal study of environmental tobacco smoke exposure in children: parental self reports versus age dependent biomarkers. BMC Public Health. 2008; 8:47. https://doi.org/10.1186/1471-2458-8-47 PMID: 18254964

19. Spanier AJ, Kahn RS, Xu Y, Hornung R, Lanphear BP. Comparison of biomarkers and parent report of tobacco exposure to predict wheeze. J Pediatr. 2011; 159(5):776–82. https://doi.org/10.1016/j.jpeds.2011.04.025 PMID: 21645908

20. Florath I, Kohler M, Weck MN, Brandt S, Rothenbacher D, Schöttker B, et al. Association of pre- and post-natal parental smoking with offspring body mass index: an 8-year follow-up of a birth cohort. Pediatri. Obes. 2014; 9(2):121–34. https://doi.org/10.1111/j.2047-6310.2012.00146.x PMID: 23420701

21. Wang I-J, Chen S-L, Lu T-P, Chuang EY, Chen P-C. Prenatal smoke exposure, DNA methylation, and persistent pulmonary hypertens ion of the newborn. Environ Health Perspect. 1997; 105(2):202–6. https://doi.org/10.1289/ehp.9710520 PMID: 9105795

22. Howrylak JA, Spanier AJ, Huang B, Peake RWA, Kellogg MD, Sauers H, et al. Cotinine in children admitted for asthma and readmission. Pediatrics. 2014; 133(2):e355–362. https://doi.org/10.1542/peds.2013-2422 PMID: 24446348

23. West HW, Juonala M, Gall SL, Kahonen M, Laitinen T, Ta Itonen L, et al. Exposure to parental smoking in childhood is associated with increased risk of carotid atherosclerotic plaque in adulthood: the Cardiovascular Risk in Young Finns Study. Circulation. 2015; 131(14):1239–46. https://doi.org/10.1161/CIRCULATIONAHA.114.013485 PMID: 25802269

24. Hedengran KK, Andersen MR, Szecsi PB, Lindh C, Uldbjerg N, Stender S. Environmental tobacco smoke exposure during pregnancy has limited effect on infant birthweight and umbilical vein endothelial nitric oxide synthase. Acta Obstet Gynecol Scand. 2019; 98(11):1309–16. https://doi.org/10.1111/aogs.13419 PMID: 29969842

25. Chelchowska M, Maciejewski TM, Mazur J, Gajewska J, Zasimович A, Ołtarzewski M, et al. Active Tobacco Smoke Exposure in Utero and Concentrations of Hepcidin and Selected Iron Parameters in Newborns. Int J Environ Res Public Health. 2019; 16(11). https://doi.org/10.3390/ijerph16111996 PMID: 31195607

26. Rovio SP, Pihlman J, Pahkala K, Juonala M, Magnusson CG, Pitkänen N, et al. Childhood Exposure to Parental Smoking and Midlife Cognitive Function. Am J Epidemiol. 2020; 189(11):1280–91. https://doi.org/10.1093/aje/kwaa052 PMID: 32242223

27. Luck W, Nau H. Nicotine and cotinine concentrations in serum and urine of infants exposed via passive smoking or milk from smoking mothers. J Pediatr. 1985; 107(5):816–20. https://doi.org/10.1016/s0022-3476(85)80427-3 PMID: 4056988
28. Ahlsten G, Tuvemo T, Gebre-Medhin M. Selected trace elements and proteins in serum of apparently healthy newborn infants of mothers who smoked during pregnancy. Acta Paediatr Scand. 1989; 78(5):671–6. https://doi.org/10.1111/j.1651-2227.1989.tb11124.x PMID: 2596272

29. Centers for Disease Control and Prevention (CDC). Preliminary data: exposure of persons aged > or = 4 years to tobacco smoke—United States, 1988–1991. MMWR Mortal Mortal Wkly Rep. 1993; 42(2):37–9. PMID: 8419790

30. Bardy AH, Seppälä T, Lillsunde P, Koskela P, Gref CG. Objectively measured tobacco exposure among pregnant women in Finland in 1986 and 1990. Acta Obstet Gynecol Scand. 1994; 73(1):30–4. https://doi.org/10.3109/0001634940913389 PMID: 8304021

31. Bardy AH, Seppälä T, Lillsunde P, Kataja JM, Koskela P, Pikkarainen J, et al. Objectively measured tobacco exposure during pregnancy: neonatal effects and relation to maternal smoking. J Obstet Gynaecol. 1993; 100(8):721–6. https://doi.org/10.1111/j.1471-0528.1993.tb14262.x PMID: 8399009

32. Rühle W, Graf von Balleström CL, Pult HM, Gnirs J. [Correlation of cotinine level in amniotic fluid, umbilical artery blood and maternal blood]. Geburtshilfe Frauenheilkd. 1995; 55(3):156–9. https://doi.org/10.1055/s-2007-1022795 PMID: 7665063

33. Pirkle JL, Flegal KM, Bernert JT, Brody DJ, Etzel RA, Maurer KR. Exposure of the US population to environmental tobacco smoke: the Third National Health and Nutrition Examination Survey, 1988 to 1991. JAMA. 1996; 275(16):1233–40. PMID: 8601954

34. Mannino DM, Moorman JE, Kingsley B, Rose D, Repace J. Health effects related to environmental tobacco smoke exposure in children in the United States: data from the Third National Health and Nutrition Examination Survey. Arch Pediatr Adolesc Med. 2001; 155(1):36–41. https://doi.org/10.1001/archpedi.155.1.36 PMID: 11177060

35. Strauss RS. Environmental tobacco smoke and serum vitamin C levels in children. Pediatrics. 2001; 107(3):540–2. https://doi.org/10.1542/peds.107.3.540 PMID: 1130596

36. Mannino DM, Caraballo R, Benowitz N, Repace J. Predictors of cotinine levels in US children: data from the Third National Health and Nutrition Examination Survey. Chest. 2001; 120(3):718–24. https://doi.org/10.1378/chest.120.3.718 PMID: 1155498

37. Lieu JEC, Feinstein AR. Effect of gestational and passive smoke exposure on ear infections in children. Arch Pediatr Adolesc Med. 2002; 156(2):147–54. https://doi.org/10.1001/archpedi.156.2.147 PMID: 11814376

38. Mannino DM, Homa DM, Redd SC. Involuntary smoking and asthma severity in children: data from the Third National Health and Nutrition Examination Survey. Chest. 2002; 122(2):409–15. https://doi.org/10.1378/chest.122.2.409 PMID: 12171810

39. Rubin RN, Navon L, Cassano PA. Relationship of serum antioxidants to asthma prevalence in youth. Am J Respir Crit Care Med. 2004; 169(3):393–8. https://doi.org/10.1164/rccm.200301-055OC PMID: 14630617

40. Aligne CA, Moss ME, Auinger P, Weitzman M. Association of pediatric dental caries with passive smoking. JAMA. 2003; 289(10):1258–64. https://doi.org/10.1001/jama.289.10.1258 PMID: 12833187

41. Wilkinson JD, Arheart KL, Lee DJ. Accuracy of parental reporting of secondhand smoke exposure: The National Health and Nutrition Examination Survey III. Nicotine Tob Res. 2006; 8(4):591–7. https://doi.org/10.1080/14622200600790021 PMID: 16920657

42. Pirkle JL, Benert JT, Caudill SP, Sosnoff CS, Pechacek TF. Trends in the exposure of nonsmokers in the U.S. population to secondhand smoke: 1988–2002. Environ Health Perspect. 2006; 114(6):853–8. https://doi.org/10.1289/ehp.8850 PMID: 16759984

43. Franchini M, Caruso C, Perico A, Pacifi R, Monleon T, Garcia-Algar O, et al. Assessment of foetal exposure to cigarette smoke after recent implementations of smoke-free policy in Italy. Acta Paediatr. 2008; 97(5):546–50. https://doi.org/10.1111/j.1651-2227.2008.00762.x PMID: 18394097

44. Max W, Sung H-Y, Shi Y. Who is exposed to secondhand smoke? Self-reported and serum cotinine measured exposure in the U.S., 1999–2006. Int J Environ Res Public Health. 2009; 6(5):1633–48. https://doi.org/10.3390/ijerph.6051633 PMID: 19543411

45. Dixon SL, Gaitens JM, Jacobs DE, Strauss W, Nagaraj A, Pivetz T, et al. Exposure of U.S. children to residential dust lead, 1999–2004: II. The contribution of lead-contaminated dust to children’s blood lead levels. Environ Health Perspect. 2009; 117(3):468–74. https://doi.org/10.1289/ehp.111918 PMID: 19337524

46. Centers for Disease Control and Prevention (CDC). Vital signs: nonsmokers’ exposure to secondhand smoke—United States, 1999–2008. MMWR Morb Mortal Wkly Rep. 2010; 59(35):1141–6. PMID: 20829748
47. Dove MS, Dockery DW, Connolly GN. Smoke-free air laws and secondhand smoke exposure among nonsmoking youth. Pediatrics. 2010; 126(1):80–7. https://doi.org/10.1542/peds.2009-3462 PMID: 20530079
48. Vesper HW, Caudill SP, Osterloh JD, Meyers T, Scott D, Myers GL. Exposure of the U.S. population to acrylamide in the National Health and Nutrition Examination Survey 2003–2004. Environ Health Perspect. 2010; 118(2):278–83. https://doi.org/10.1289/ehp.0901021 PMID: 20123601
49. XU, Cook RL, Ilaquva VA, Kan H, Talbott EO. Racial differences in the effects of postnatal environmental tobacco smoke on neurodevelopment. Pediatrics. 2010; 126(4):705–11. https://doi.org/10.1542/peds.2009-3589 PMID: 20855396
50. Guerrero-Preston R, Goldman LR, Brebi-Mievil P, Ili-Gangas C, Lebron C, Witter FR, et al. Global DNA hypomethylation is associated with in utero exposure to cotinine and perfluorinated alkyl compounds. Epigenetics. 2010; 5(6):539–46. https://doi.org/10.4161/epi.5.6.12378 PMID: 20523118
51. Sharief S, Jariwala S, Kumar J, Muntner P, Melamed ML. Vitamin D levels and food and environmental allergies in the United States: results from the National Health and Nutrition Examination Survey 2005–2006. J Allergy Clin Immunol. 2011; 127(5):1195–202. https://doi.org/10.1016/j.jaci.2011.01.017 PMID: 21329969
52. Cardwell K, Pan Z, Boucher R, Zuk J, Friesen RH. Screening by pulse CO-oximetry for environmental tobacco smoke exposure in preanesthetic children. Paediatr Anaesth. 2012; 22(9):859–64. https://doi.org/10.1111/j.1460-9592.2012.03867.x PMID: 22587734
53. Dempsey DA, Meyers MJ, Oh SS, Nguyen EA, Fuentes-Afflick E, Wu AHB, et al. Determination of tobacco smoke exposure by plasma cotinine levels in infants and children attending urban public hospital clinics. Arch Pediatr Adolesc Med. 2012; 166(9):851–6. https://doi.org/10.1001/archpediatrics.2012.170 PMID: 22566513
54. Andersen SL, Nehr SB, Wu CS, Olsen J, Pedersen KM, Laurberg P. Thyroglobulin in smoking mothers and their newborns at delivery suggests autoregulation of placental iodide transport overcoming thiocyanate inhibition. Eur J Endocrinol. 2013; 168(5):723–31. https://doi.org/10.1530/EJE-12-0759 PMID: 23444413
55. Kit BK, Simon AE, Brody DJ, Akinbami LJ. US prevalence and trends in tobacco smoke exposure among children and adolescents with asthma. Pediatrics. 2013; 131(3):407–14. https://doi.org/10.1542/ pediatrics.2012-2328 PMID: 23900612
56. Pino P, Walter T, Oyarzun MJ, Burden MJ, Lozoff B. Rapid drop in infant blood lead levels during the transition to unleaded gasoline use in Santiago, Chile. Arch Environ Health. 2004; 59(4):182–7. https://doi.org/10.3200/AEOH.59.4.182-187 PMID: 16189990
57. Mason J, Wheeler W, Brown MJ. The economic burden of exposure to secondhand smoke for child and adult never smokers residing in U.S. public housing. Public Health Rep. 2013; 130(3):230–44. https://doi.org/10.1177/0033354913503303 PMID: 25931627
58. Merianos AL, Jandarov RA, Mahabee-Gittens EM. Secondhand Smoke Exposure and Pediatric Health-care Visits and Hospitalizations. Am J Prev Med. 2017; 53(4):441–8. https://doi.org/10.1016/j.amepre.2017.03.020 PMID: 28532658
59. Yilmaz O, Turkeli A, Onur E, Bilge S, Yuksel H. Secondhand tobacco smoke and severity in wheezing children: Nasal oxidant stress and inflammation. J Asthma. 2018; 55(5):477–82. https://doi.org/10.1080/02770903.2017.1350070 PMID: 28881145
60. Shenassa ED, Rossen LM, Cohen J, Morello-Frosch R, Payne-Sturges DC. Income Inequality and US Children's Secondhand Smoke Exposure: Distinct Associations by Race-Ethnicity. Nicotine Tob Res. 2017; 19(11):1292–9. https://doi.org/10.1093/ntr/ntw293 PMID: 27811157
61. Nwosu BU, Kum-Nji P. Tobacco smoke exposure is an independent predictor of vitamin D deficiency in US children. PLoS ONE. 2018; 13(10):e0205342. https://doi.org/10.1371/journal.pone.0205342 PMID: 30296288
62. Brody DJ, Lu Z, Tsai J. Secondhand Smoke Exposure Among Nonsmoking Youth: United States, 2013–2016. NCHS Data Brief. 2019;(348):1–8. PMID: 31442196
63. Biren C, Zhang L, Bhandari D, Blount BC, De Jesus VR. Isoprene Exposure in the United States Based on Urinary IPM3: NHANES 2015–2016. Environ Sci Technol. 2020; 54(4):2370–8. https://doi.org/10.1021/acs.est.9b06587 PMID: 31961658
64. Benowitz NL, Hukkanen J, Jacob P. Nicotine chemistry, metabolism, kinetics and biomarkers. Handb Exp Pharmacol. 2009;(192):29–60. https://doi.org/10.1007/978-3-540-65248-5_2 PMID: 19164645
65. Kehl D, Thyrian JR, Lüdemann J, Nauck M, John U. A descriptive analysis of relations between parents’ self-reported smoking behavior and infants’ daily exposure to environmental tobacco smoke. BMC Public Health. 2010; 10:424. https://doi.org/10.1186/1471-2458-10-424 PMID: 20642817
66. Dempsey D, Jacob P, Benowitz NL. Nicotine metabolism and elimination kinetics in newborns. Clin Pharmacol Ther. 2000; 67(5):458–65. https://doi.org/10.1067/mcp.2000.106129 PMID: 10824624

67. Homa DM, Neff LJ, King BA, Caraballo RS, Bunnell RE, Babb SD, et al. Vital signs: disparities in non-smokers’ exposure to secondhand smoke—United States, 1999–2012. MMWR Morb Mortal Wkly Rep. 2015; 64(4):103–8. PMID: 25654612

68. Schick S, Glantz S. Philip Morris toxicological experiments with fresh sidestream smoke: more toxic than mainstream smoke. Tob Control. 2005; 14(6):396–404. https://doi.org/10.1136/tc.2005.011288 PMID: 16319363

69. Domino EF, Hornbach E, Demana T. The nicotine content of common vegetables. N Engl J Med. 1993; 329(6):437. https://doi.org/10.1056/NEJM199308053290619 PMID: 8326992

70. Davis RA, Stiles MF, deBethizy JD, Reynolds JH. Dietary nicotine: a source of urinary cotinine. Food Chem Toxicol. 1991; 29(12):821–7. https://doi.org/10.1016/0278-6915(91)90109-k PMID: 1765327

71. Yolton K, Dietrich K, Auinger P, Lanphear BP, Hornung R. Exposure to environmental tobacco smoke and cognitive abilities among U.S. children and adolescents. Environ Health Perspect. 2005; 113(1):98–103. https://doi.org/10.1289/ehp.7210 PMID: 15626655

72. Apostolou A, Garcia-Esquinas E, Fadrowski JJ, McLain P, Weaver VM, Navas-Acien A. Secondhand tobacco smoke: a source of lead exposure in US children and adolescents. Am J Public Health. 2012; 102(4):714–22. https://doi.org/10.2105/AJPH.2011.300161 PMID: 21852639

73. Jarvis MJ, Fidler J, Mindell J, Feyerabend C, West R. Assessing smoking status in children, adolescents and adults: cotinine cut-points revisited. Addiction. 2008; 103(9):1553–61. https://doi.org/10.1111/j.1360-0443.2008.02297.x PMID: 18783507

74. Mourino N, Pérez-Ríos M, Santiago-Pérez MI, Lanphear B, Yolton K, Braun JM. Secondhand tobacco smoke exposure among children under 5 years old: questionnaires versus cotinine biomarkers: a cohort study. BMJ Open. 2021; 11(6):e044829. https://doi.org/10.1136/bmjopen-2020-044829 PMID: 34183339